 |
|
Does Aspirin Attenuate the Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Heart Failure?
Tomasz Stys, MD;
William E. Lawson, MD;
Gerald C. Smaldone, MD, PhD;
Adam Stys, MD
Arch Intern Med. 2000;160:1409-1413.
Ischemic heart disease is the most common underlying cause of congestive heart failure, and thus aspirin (acetylsalicylic acid [ASA]) and angiotensin-converting enzyme (ACE) inhibitors are commonly used together for treatment in this setting. The issue of possible attenuation of the effect of ACE inhibitors by ASA has been an area of intense debate. Currently, it is perceived that a significant part of the beneficial effect of ACE inhibitors is related to augmentation of bradykinin levels, which among other effects stimulate the release of prostacyclin. Aspirin, on the other hand, inhibits the production of prostacyclin by blocking cyclooxygenase. Prostaglandins play an important endogenous vasodilatory role and counteract the enhanced peripheral vasoconstriction state in congestive heart failure. Thus, the counteracting effect of ASA on the augmentation of prostacyclin synthesis by ACE inhibitors could result in a potential reduction of the beneficial effects of the ACE inhibitor's and could be of great importance. This article reviews reports from large clinical trials pertaining to this issue and relates their findings to the currently available theoretical bases for support of the counteracting effect of ASA on augmentation of prostacyclin synthesis by ACE inhibitors. The clinical implications of such an interaction are discussed.
From the Cardiology Division (Drs T. Stys and Lawson) and Pulmonary and Critical Care Medicine Division (Dr Smaldone), Department of Medicine, State University of New York, Stony Brook, and Sioux Valley Canby Campus, Canby, Minn (Dr A. Stys).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Aspirin-Angiotensin-Converting Enzyme Inhibitor Coadministration and Mortality in Patients With Heart Failure: A Dose-Related Adverse Effect of Aspirin
Guazzi et al.
Arch Intern Med 2003;163:1574-1579.
ABSTRACT
| FULL TEXT
The Platelet in Diabetes: Focus on prevention of ischemic events
Colwell and Nesto
Diabetes Care 2003;26:2181-2188.
ABSTRACT
| FULL TEXT
Assessment of endothelial damage and dysfunction: observations in relation to heart failure
Chong et al.
QJM 2003;96:253-267.
FULL TEXT
Analysis of a Large Cohort of Health Maintenance Organization Patients With Congestive Heart Failure
Gladowski et al.
American Journal of Medical Quality 2003;18:73-81.
ABSTRACT
Preventing stroke
Schrader and Luders
BMJ 2002;324:687-688.
FULL TEXT
Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy: A Statement for Healthcare Professionals From the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association
Schoolwerth et al.
Circulation 2001;104:1985-1991.
FULL TEXT
|
